Adaptimmune

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company developing engineered T-cell therapies to treat solid tumor cancers. The company's proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. 

Adaptimmune's lead product, TECELRA (afamitresgene autoleucel), received FDA accelerated approval in August 2024 for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy. TECELRA is the first engineered cell therapy approved for a solid tumor cancer in the US and the first new therapy option for synovial sarcoma in over a decade. 

As of August 2024, the company was also advancing other candidates targeting MAGE-A4, NY-ESO-1, and additional cancer antigens. Adaptimmune has R&D operations in Philadelphia, Pennsylvania and Oxford, UK. The company manufactures its cell therapies at its facility in Philadelphia's Navy Yard.

Key customers and partnerships

Adaptimmune has entered several strategic collaborations to advance its cell therapy pipeline. In May 2024, the company partnered with Galapagos NV to evaluate uza-cel, Adaptimmune's next-generation MAGE-A4 TCR T-cell therapy, using Galapagos' decentralized manufacturing platform for head and neck cancer. Adaptimmune previously had partnerships with GSK , Astellas , and Roche/Genentech (ended in April 2024 ). 

The company works with various cancer centers and hospitals as clinical trial sites and authorized treatment centers for TECELRA. Adaptimmune has also partnered with diagnostic companies Agilent Technologies and Thermo Fisher Scientific to develop companion diagnostics for patient selection. Adaptimmune planned to onboard approximately 30 treatment centers for TECELRA within two years of approval.